Economic Times | Novartis heart failure drug gets FDA incentives Yahoo! New Zealand News NEW YORK (AP) -- Novartis AG said Friday its drug serelaxin, a treatment for acute heart failure, received breakthrough therapy status from the Food and Drug Administration. The drug is intended to treat symptoms of acute heart failure episodes ... US FDA deems Novartis' heart failure candidate a 'breakthrough' FDA grants Breakthrough Therapy designation to Novartis' serelaxin (RLX030 ... Novartis Heart-Failure Drug Wins 'Breakthrough' Status at FDA |
